Escala de Gravidade e Habilidade Funcional para pacientes com Esclerose Lateral Amiotrófica:

Resultados Preliminares

Autores

  • Marco Orsini Physical Therapist, Chair of the Neurological Rehabilitation, Escola Superior de Ensino Helena Antipoff (ESEHA) and Neuroscience Researcher at UFF.
  • Marcos RG de Freitas Neurologist, Chair of the Neurology Department and Head of Clinical Neurology Staff, UFF.
  • Mariana Pimentel de Mello Physical therapist, Department of Neuroscience, UFF.
  • Clayton Amaral Domingues Neuropsychiatry Institute, Instituto de Psiquiatria da Universidade do Brasil, UFRJ.
  • José Mauro Brás Lima Neurolgist, Neurology Department, Deolindo Couto Neurology Institute, UFRJ.
  • Marli Pernes Neurolgist, Neurology Department, Deolindo Couto Neurology Institute, UFRJ.
  • Cláudio Heitor Gress Neurolgist, Neurology Department, Deolindo Couto Neurology Institute, UFRJ.
  • Acary Souza Bulle Oliveira MD, PhD, Neurologist, Department of Neurology, Unifesp.
  • Carlos Henrique Melo Reis Neurologist, Neurology Department, UFF.
  • Wandilson Wandilson Júnior Neurologist, Neurology Department, UFF.
  • Giseli Quintanilha Neurologist, Neurology Department, UFF.
  • Eduardo B Cavalcanti Medical Student, UFF.
  • Luciane Bizari Coin de Carvalho PhD, Psychologist, Neuro-Sono, Department of Neurology, Universidade Federal de São Paulo.

DOI:

https://doi.org/10.34024/rnc.2008.v16.8632

Palavras-chave:

Esclerose Lateral Amiotrófica, Escalas, Doenças Neuromusculares

Resumo

Introdução. A esclerose lateral amiotrófica (ELA) é uma doença progressiva e fatal que afeta os neurônios do feixe piramidal e da ponta anterior da medula espinhal. Inúmeras avaliações têm sido propostas no sentido de fornecer um melhor acompanhamento dos indivíduos e gerenciamento das complicações secundárias. Apresentamos, no presente estudo, um novo instrumento para acompanhamento clínico e reabilitativo de pacientes com ELA. Método. Avaliamos 96 pacientes consecutivos com diagnóstico de ELA, no Hospital Universitário Antonio Pedro e no Instituto de Neurologia Deolindo Couto com a Escala de Gravidade e Habilidade Funcional. Resultados. Estes dados preliminares permitiram delinear uma escala de 5 domínios que mensuram 1) força muscular em miótomos específicos, 2) habilidades funcionais, 3) deglutição 4) respiração, and 5) estágio de gravidade da doença. As características clínicas e manifestações funcionais dos pacientes com ELA foram heterogêneas em relação as complicações mais freqüentes e ao nível de independência funcional. Conclusão. Estes resultados preliminares sugerem que nossa escala de 5 domínios é simples, de fácil aplicabilidade, não demorada, assim como facilmente reprodutível a respeito do curso clínico e do prognóstico dos pacientes com ELA. Nosso estudo piloto garante a etapa seguinte de nossa pesquisa que inclui a exatidão, validade interna, a confiabilidade, análise fatorial e outros procedimentos
metodológicos e estatísticos formais necessários.

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...

Referências

Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model of survival prediction. Brain 1995;118:707-19.

Rosenfeld J, Jackson CE. Quantitative assessment and outcome measures in neuromuscular disease. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE (eds.) Neuromuscular Disorders in Clinical Practice. Boston: Butterworth Heinemann, 2002, 1416p.

Guccione AA. Physical therapy diagnosis and the relationship between impairments and function. Phys Ther 1991;71:499-504.

Cudkowicz M, Qureshi M, Shefner J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx 2004;1(2): 273-83.

Stambler N, Charatan M, Cedarbaum J. Prognostic indicators of survival in ALS. Neurology 1998;50:66-72.

Damiano AM, Patrick DL, Guzman GI, Gawel MJ, Gelinas DF, Natter HM, et al. Measurement of health-related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies. Med Care 1999;37(1): 15-26.

Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revised: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotr Lat Scler Other Motor Neuron Disord 2000;1(5):293-9.

Medical Research Council. Aids to the examination of the peripheral nervous system. Edinburgh: WB Saunders, 2000, 1-2.

Czaplinski A, Yen AA, Appel SH. Amyotrophic Lateral Sclerosis: early predictors of prolonged survival. J Neurol 2006; 253:1428-36.

Noonan CW, White MC, Thurman D, Wong LY. Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998. Neurology 2005;64:1215-21.

Del Aguila MA, Longstreth WT, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60:813-9.

Brooks BR. Clinical epidemiology of amyotrophic lateral sclerosis. Neurol Clin 1996:14:399-420.

Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-15.

Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003;61:456-64.

Werneck LC, Bezerra R, Neto OS, Scola RH. A clinical epidemiological study of 251 cases of amyotrophic lateral sclerosis in the south of Brazil. Arq Neuropsiquiatr 2007;65(2A):189-95.

Mitsumoto H, Rabkin JG. Palliative care for patients with amyotrophic lateral sclerosis: prepare for the worst and hope for the best. JAMA 2007;298(2):207-16.

Pozza AM, Delamura MK, Ramirez C, Valério NI, Marino LHC, Lamari NM. Physiotherapeutic conduct in amyotrophic lateral sclerosis. São Paulo Med J 2006;124(6):350-4.

Miller RG, Anderson FA, Bradley WG, Brooks BR, Mitsumoto H, Munsat TL, et al. The ALS patient care database: goals, design, and early results. ALS C.A.R.E. Study Group. Neurology 2000;54(1):53-7.

Trifirò G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, et al. Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003–2004, Pharmacoepidemiol Drug Saf 2007;16(5):552-9.

Gordon T, Hegedus J, Tam SL. Adaptive and maladaptive motor axonal sprouting in aging and motoneuron disease. Neurol Res 2004;26(2):174-85.

Swash M, Schwartz MS. What do we really know about amyotrophic lateral sclerosis? J Neurol Sci 1992;113:4-16.

Vainstein G, Gordon C, Gadoth N. HTLV-1 Associated Motor Neuron Disease Mimicking “Man-in-the-Barrel” Syndrome. Journal of Clinical Neuromuscular Disease 2005;6(3):127-31.

Great Lakes ALS Study Group. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 2003;61:1503-7.

Gooch CL, Shefner JM. MUNE. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(Suppl 1):104-7.

Armon C, Brandstater ME. Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve 1999;53:1239-46.

Wagner-Sonntag E, Prosiegel M. Dysphagia. In: Ollver D, Borasio GD, Walsh D (eds.). Palliative care in amyotrophic lateral sclerosis: from diagnosis to bereavement. 2 ed. Oxford: Oxford University Press, 2006, 95-109.

Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci 1999;169:118-25.

Kubler A, Nijboer F, Mellinger J, 6 autores, et al. Patients with ALS can use sensoriomotor rhythms to operate a brain-computer interface. Neurology 2005;64:1775-7.

Belsh JM, Schiffman PL (eds.). Amyotrophic lateral sclerosis: diagnosis and management for the clinician. Armonk. New York: Futura, 1996, 41-3.

Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan /quinidine: a randomized trial. Neurology 2004;63:1364-70.

Moss AH, Casey P, Stocking CB, Roos RP, Brooks BR, Siegler M. Home ventilator for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family and physician attitudes. Neurology 1993;43:438-43.

Desnuelle C, Bruno M, Soriani MH, Perrin C. Quelles sont les modalités de thérapie physique symptomatique incluant les techniques de désencombrement bronchique? Rev Neurol (Paris) 2006;162(2):4S244-52.

Downloads

Publicado

2008-09-30

Como Citar

Orsini, M., Freitas, M. R. de, Mello, M. P. de, Domingues, C. A., Lima, J. M. B., Pernes, M., Gress, C. H., Oliveira, A. S. B., Reis, C. H. M., Wandilson Júnior, W., Quintanilha, G., Cavalcanti, E. B., & Carvalho, L. B. C. de. (2008). Escala de Gravidade e Habilidade Funcional para pacientes com Esclerose Lateral Amiotrófica:: Resultados Preliminares. Revista Neurociências, 16(3), 194–203. https://doi.org/10.34024/rnc.2008.v16.8632

Edição

Seção

Artigos Originais
Recebido: 2019-03-05
Publicado: 2008-09-30

Artigos mais lidos pelo mesmo(s) autor(es)

1 2 3 4 5 6 7 8 9 10 > >>